Making norms to tackle global challenges: The role of Intergovernmental Organisations by Vilella Nilsson, A
M
I
A
C
a
A
R
R
1
A
A
K
I
G
I
G
P
1
i
c
P
n
o
n
c
r
g
p
n
e
H
h
0Research Policy 46 (2017) 171–181
Contents lists available at ScienceDirect
Research  Policy
jo ur nal ho me  page: www.elsev ier .com/ locate / respol
aking  norms  to  tackle  global  challenges:  The  role  of
ntergovernmental  Organisations
driana  Nilsson ∗
openhagen Business School, Department of Business and Politics, Steen Blichers Vej 22, 2000 Frederiksberg, Denmark
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 8 June 2015
eceived in revised form
6 September 2016
ccepted 26 September 2016
vailable online 6 October 2016
eywords:
nnovation
rand Challenges
a  b  s  t  r  a  c  t
This paper  argues  that  Intergovernmental  Organisations  (IGOs)  can  play  a signiﬁcant  role  in the  processes
of  system  transformation  required  by  Grand  Challenges.  The  reason  is their  potential  to inﬂuence  socio-
technical  regimes  connected  to policy  areas  in  which  they  have  authority.  Supported  by  mandates,  moral
standing  and  technical  expertise,  IGOs  act in  two  ways:  operating  with  high  level  of  political  support,  these
organisations  guide  priority  setting  and  norm  development  through  the  deﬁnition  of collective  problems
and  solutions,  including  STI  aspects,  establishing  a shared  vision;  involving  public  and  private  actors,  IGOs
implement  and  protect  novel  practices  that  reinforce  the new norms,  from  legally  binding  agreements  to
the  creation  of  new  spaces  for  international  collaboration.  These  processes  are  examined  here  in the  ﬁeld
of global  health,  where  outside  pressure  directed  at the  intellectual  property  rules  in connection  to  accessntergovernmental Organisations
lobal health
atent pools
to medicines  prompted  the  WHO  to  deﬁne  the  health  challenge  as  a need  to stimulate  innovation  and
ensure  wide  access  to technology  at the  same  time.  Two  of  the  solutions  implemented  by  IGOs  to  achieve
both  goals  are  analysed:  the  Medicines  Patent  Pool, designed  by UNITAID  to  fulﬁl  access  and  innovation
needs  in  relation  to  HIV/AIDS  drugs,  and  WIPO  Re:Search,  set  up  by WIPO  to support  collaboration  and
accelerate  discovery  and  product  development  for Neglected  Tropical  Diseases,  Malaria  and  Tuberculosis.
© 2016  The  Author(s).  Published  by Elsevier  B.V. This  is  an open  access  article  under  the CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
There is widespread agreement that science, technology and
nnovation (STI) have a role in helping countries tackle social
hallenges such as climate change, pollution and public health.
roviding comprehensive solutions for these global and intercon-
ected problems, however, exceeds the capacity of single states
r market forces alone. By deﬁnition, Grand Challenges involve “a
eed to cooperate worldwide to create public goods (mitigation of
limate change, health), or protect the global commons (the envi-
onment, ﬁsheries)” (OECD, 2010, p.165), calling for action that
oes beyond the conventional role played by governments. For
olicy-makers, thus, the task is also about how to develop and align
ew policies and practices to address shared societal problems and
nhance the impact of solutions.
∗ Present address: University of Liverpool, School of Management, Chatham
ouse, Liverpool, United Kingdom.
E-mail address: adriana.nilsson@liverpool.ac.uk
ttp://dx.doi.org/10.1016/j.respol.2016.09.012
048-7333/© 2016 The Author(s). Published by Elsevier B.V. This is an open access articleThe term Grand Challenges was added to the EU policy termi-
nology in the late 2000 s (EU, 2008)1, fuelling scholarly interest in
the role of STI in strategic responses to collective problems. Part
of this work aimed at deﬁning and understanding their character-
istics, with one aspect regarded as particularly important: Grand
Challenges are qualitatively different from traditional STI concerns,
often considered under the logic of national systems of innovation
geared towards economic growth (Gassler et al., 2008; Kallerud
et al., 2013). Developing technical solutions to achieve relatively
uncontested goals is a far cry from the much messier business of
mobilising and integrating different actors and perspectives across
policy issues and geographical lines to set priorities and agree on
solutions in which STI plays a role.
In other words, tackling Grand Challenges requires a broader
perspective and calls for system transformation (Mowery et al.,
2010), an exercise that involves not only “innovation as tradition-
ally studied and stimulated, but also novel ways of assembling
and re-assembling heterogeneous bits of work (including tradi-
1 D 31 billion was  allocated to the EU’s Framework Programme for Research and
Innovation 2014–2020 to address seven Grand Challenges: Health and Wellbeing;
Food security; Transport; Energy; Climate Action; Society: and Security.
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ional innovation) into evolving constellations that address a Grand
hallenge” (Kuhlmann and Rip, 2014, p.4). When policy-making
ims solely at technology-speciﬁc change, the connections with
olicy arenas hosting “other types of policies, actors and discur-
ive spheres” are missed (Weber and Rohracher, 2012). In the same
ay, when scholarly attention is placed mainly on the role of gov-
rnments as providers of R&D and funding, complementary actors
nd initiatives remain under the radar.
This paper aims to contribute to this debate by making a case
or Intergovernmental Organisations (IGOs) as an important actor
n processes of system transformation. More speciﬁcally, it brings
nsights from the discipline of International Relations (IR) to reﬂect
n IGO’s contribution. The short answer is that IGOs can aid tran-
ition processes by inﬂuencing norms and practices in the policy
reas where they have authority. Endowed with a rational-legal
uthority sustained by mandates, moral standing and technical
xpertise, IGOs operate with high level political support to create
ules able to impact socio-technical regimes, deﬁned here as “the
emi-coherent set of rules that orient and coordinate the activities
f the social groups that reproduce the various elements of socio-
echnical systems” (Geels, 2011; p.27). This is done in two  ways: by
eﬁning the challenges and the best solutions to them, including
TI aspects, creating a collective vision and direction for action; and,
y involving private and public actors in novel practices that rein-
orce this new direction, ranging from legally binding agreements
o the creation of protected spaces that support new transnational
nstruments.
To illustrate, I examine two interconnected processes: the devel-
pment of a new vision in public health, in which the promotion
f needs-driven health innovation and its equitable dissemination
re considered fundamental to address the global burden of dis-
ase, making innovation and access two sides of the same coin;
nd the establishment of two mechanisms designed to achieve
hese goals. The ﬁrst is the Medicines Patent Pool (MPP), set up and
unded by UNITAID, part of the World Health Organisation (WHO),
o accelerate the development and availability of HIV/AIDS drugs
t affordable prices. The second is WIPO Re:Search, a consortium
eveloped by the World Intellectual Property Organisation (WIPO)
o facilitate sharing of intellectual property (IP) assets and know-
ow in relation to Neglected Tropical Diseases (NTDs), Malaria and
uberculosis (TB).
The debate was triggered in the 1990s after a change in inter-
ational rules: the creation of a standardised and global system
f IP protection through the Trade Related Aspects of Intellectual
roperty Rights (TRIPS) Agreement. Political pressure, driven by
riticism articulated by social movements, led states to reinforce
he WHO  mandate to explore consequences of the treaty for public
ealth. The initial aim of increasing access to medicines for infec-
ious epidemics in developing countries through TRIPS ﬂexibilities
as, since the signature of the Doha Declaration, in 2001, widened
o comprise STI practices and a broader range of diseases and tech-
ologies relevant for developed nations. Solutions involve different
inds of expertise and depend on interactions between health and
ther policy domains, including development, IP and international
rade.
This article proceeds as follows: the next section reviews the
iterature on Grand Challenges and introduces the literature on
GOs to make a case for their role in supporting transitions. Sec-
ion three describes the research design. Section four reviews the
ccess to medicines, IP rights and innovation debate and analy-
es the IGO-led process of shaping the deﬁnition of the problems
nd solutions. Section ﬁve examines the MPP  and WIPO Re:Search,
nd the involvement of IGOs in establishing and supporting new
ctivities aiming to achieve innovation and access. 46 (2017) 171–181
2. Global challenges and system transformation
The inclusion of Grand Challenges as an important target for STI
policy at national and international levels, and the recognition of
the different nature of these collective problems (JIPP, 2012; OECD,
2011), have triggered a series of studies attempting to understand
and improve their governance. The need to engage heterogeneous
actors and manage their interaction has brought the issue of coor-
dination and cooperation to the fore (Edler, 2010; Prange-Gstöhl,
2010), while the governance of transnational programmes have
been evaluated on their ability to support priority setting, ﬁnancing,
knowledge sharing, outreach and capacity-building to aid problem
solving and diffusion (OECD, 2012).
Part of the academic work on the issue has focused on policy
instruments and their potential for addressing Grand Challenges. A
whole Research Policy special issue was dedicated to the scrutiny of
mission R&D programmes in the health, agriculture, energy and
defence sectors, including analyses of demand side instruments
such as public procurement for innovation, and the use of prizes and
regulation (Foray et al., 2012b). These accounts highlight the differ-
ent problems involved in solving Grand Challenges in comparison
to narrower missions and propose a basis for better programme
design. This literature, however, has been criticised for not address-
ing the transformative character of Grand Challenges by conﬁning
the role of governments to R&D and funding; giving little consider-
ation to alternative actors; and, focusing on end-goals rather than
on open-ended processes (Kuhlmann and Rip, 2014).
2.1. The rationale for a multi-level approach
The problem partly stems from the current logic of the inno-
vation systems approach, which aims at optimising ﬁrm-based
innovation processes for economic growth (Foray et al., 2012a;
Mowery et al., 2010). Weber and Rohracher (2012) argue that poli-
cies seeking to stimulate innovation at the micro-level need to be
complemented by multi-level, transition-oriented policies able to
deal with the more contested and non-linear political and policy
processes involved in determining and supporting societal goals.
Engaging with the transitions literature, the authors build on the
multi-level perspective in which niches, regimes and landscapes
interact and align to bring about system transformation. Their argu-
ment is that placing emphasis on regimes, deﬁned around societal
functions and needs, the multi-level approach can help “high-
light the way these needs are fulﬁlled, the role of demand and
use, and the inter-linkage of institutions, technologies and social
practices”, complementing the narrower focus of systems of inno-
vation (Weber and Rohracher, 2012; 1039). The combination of the
two frameworks leads to the identiﬁcation of four shortcomings
that can hinder system transformation: directionality (identiﬁca-
tion of problems and establishment of shared visions, including
requirements outside the innovation system); demand articulation
(enabling the uptake of innovations by users); policy coordination
(between national, regional and sectoral actors, but also between
STI and sectoral policies); and, reﬂexivity (ability to monitor and
involve actors in self-governance).
Adopting the multi-level approach not only helps unearthing
failures that can hinder system transformation, but also highlights
the role of regimes, and of regime change, in transformative path-
ways. As “the semi-coherent set of rules that orient and coordinate
the activities of the social groups that reproduce the various ele-
ments of socio-technical systems” (Geels, 2011), socio-technical
regimes tend to stability and have structuring effects, functioning
as inhibiting factors that resist change (Kemp et al., 2001). Because
of this stickiness, the transition approach has traditionally traced
transformative processes back to activities initiated at niche/micro
level (Berkhout et al., 2004), where “it is possible to deviate from the
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ules in the existing regime” (Geels, 2004; p.912). New technologies
nd practices, therefore, can be nurtured in a protected environ-
ent and managed in ways that support regime transformation
Kemp et al., 2001, 1998).
Direct regime change prompted by top down internal and exter-
al pressures, however, are increasingly being examined. Berkhout
t al. (2004) consider four types of regime transitions, includ-
ng purposive transitions in which a broader set of interests,
ostly located outside the regime in question, target the current
egime. These processes are commonly initiated by the engage-
ent of interest groups attempting to change landscape variables.
eels and Schot (2007) add timing and the nature of multi-level
nteractions to propose four different pathways in which transfor-
ation is likely to be preceded by regime-adjustment activities. In
heir typology, landscape pressures initiated by actors outside the
egime, such as social movements or professionals, lead to an inter-
ediate phase of adjustment and reorientation of regime rules by
ncumbent actors before transformation is achieved.
Change, therefore, happens when the interrelated rules that
ake up socio-technical regimes become misaligned (Geels, 2004;
.905), prompting regime-adjustment that aims at restoring coher-
nce. This process precedes system transformation. International
egimes studied in the discipline of IR, are part of these interrelated
ules: intellectual property, trade, tax and environment agreements
re just a few of the international frameworks that are linked to sys-
ems of innovation. If rules created at international level are part
f this alignment, agency at this level has, accordingly, potential to
rigger tensions and misalignments in socio-technical regimes and
park changes that can lead to the system transformations required
y Grand Challenges. This takes us to IGOs.
.2. The role of IGOs
The debate on how international institutions and regimes inﬂu-
nce the global political economy, and the role of IGOs in these
rocesses, has long interested IR scholars. Research has reﬂected
 divide between two traditions: rationalists, holding a state-
entric approach and focusing on the conditions by which states
ccept international regimes; and constructivists, considering a
arge number of actors and networks and the importance of norma-
ive sanctioning (Seabrooke, 2010). In a nutshell, rationalists take
tate engagement with regimes and IGOs to be dependent on the
xtent they can beneﬁt from them (Keohane, 1989; Simmons and
lkins, 2004); constructivists, on the other hand, expose the lim-
ts of instrumentality and highlight a logic of appropriateness, in
hich norms and ideas are central (Finnemore and Sikkink, 1998;
arch and Olsen, 1998).
Insights from both traditions, as well as the development of
cholarship that attempts to incorporate rationalist and construc-
ivist views, shed light on why states create IGOs, how they operate,
nd processes of policy change. Rationalist lenses are particularly
seful in explaining the conditions under which states establish
GOs and the conditions of their autonomy. Examining organisa-
ions across different policy areas, Abbott and Snidal (1998) single
ut centralisation and independence as characteristics that entice
tates to engage with IGOs. Centralisation, which allows collective
ctivities to take place under one stable organisational structure,
ncreases IGOs’ ability to shape the environment in which states
perate; independence entails a capacity to manage interstate dis-
utes in a neutral manner. Member states, however, attempt to
onstrain IGOs’ autonomy. One way this is done is through their
esign, with organisational features such as membership rules con-
idered to be the result of “rational, purposive interactions among
tates and other international actors to solve speciﬁc problems”,
referably in a way that advance states own goals (Koremenos et al.,
001; p.762). 46 (2017) 171–181 173
Rationalists have also explored issues of autonomy through
principal-agent (PA) theory, which considers the reasons for cre-
ating actors that, by pursuing their own interests, can hinder states
from pursuing theirs. The dilemma here is that while the type
of contract established between principals and agents can help
reduce agency slack (independent action by the agents against
principals’ interests) and autonomy (action that escapes control
mechanisms), it can also diminish the beneﬁts of delegation.
According to Hawkins et al. (2006), all delegation is based upon divi-
sion of labour and specialisation. Rather than performing a task, be
it for lack of willingness or capacity, states delegate the task to a spe-
cialised agent with expertise, time, political capacity or resources
to perform it. Hawkins and his colleagues, however, identify ﬁve
additional beneﬁts that may  entice states to delegate to IGOs: man-
aging policy externalities, facilitating collective decision-making,
resolving disputes, enhancing credibility and creating policy bias.
Policy externalities create a need for mutually coordinated
action to facilitate agreements. In coordination dilemmas, granting
authority to a neutral third part that evaluates alternatives through
technical standards reduces transaction costs and improves out-
comes. States also beneﬁt from delegation in collaboration
dilemmas such as provision of public goods, when IGOs may be
tasked with providing the goods or collecting information about
individual efforts to provide them. Decision making problems can
be aided by the delegation of authority to an agenda-setting agent
able to bring policy choices closer to the collective preference.
Impartial and autonomous agents can also help resolve disputes
between states, securing the “social beneﬁts of cooperation”. The
credibility of policy commitments, on the other hand, may  be
enhanced by delegating authority to enforcing agents with high
discretion and clear preferences to move policy in the desired
direction. Lastly, delegation can be used to perpetuate particular
patterns of power through the structuration of incentives in ways
that protect current policy beneﬁciaries. In all these cases, however,
the probability and extent of delegation interact with preferences
and power of states (Hawkins et al., 2006, p.12–20).
PA theory, thus, recognizes that IGOs’ autonomy is a precon-
dition for their usefulness to states, but does not downplay the
importance of state preferences and power. In this view, states
and IGOs have a mutually dependent relationship (Reinalda and
Verbeek, 2003). Rationalist scholarship, however, has less to say
about how IGOs’ interests are formed, how they pursue these inter-
ests, and how they change. Constructivist scholars have developed
this research agenda further.
2.3. The creation of norms
Barnett and Finnemore (2004) argue that IGOs are better under-
stood as bureaucracies that not only pursue the tasks delegated to
them by states but develop their own  views and organisational cul-
tures to promote good policy (p.5). Their claims to authority are
based on rational-legal neutrality, delegation, expertise and their
position of defenders of common values of the international com-
munity (Barnett and Finnemore, 2004; p. 20–25). Central to their
power is their ability to transform information into knowledge that
shapes social reality and spur action, a process supported by auton-
omy  to set the agenda, decide what data should be collected and
choice of actors participating, or not, in the debate.
In this view, IGOs constitute and regulate behaviour through
three mechanisms: classifying problems, actors and actions; ﬁxing
meanings by establishing how to solve it and by whom; and, artic-
ulating and diffusing norms and rules. “IGOs deﬁne problems for
other actors (by classifying them as such), specify which actors have
responsibility for solving those problems, and use their authority to
identify the right or appropriate kind of solution for the particular
problem under consideration” (Barnett and Finnemore, 2004; p.34).
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hile these organisations play a central role in the so-called “norm
ife cycle” (Finnemore and Sikkink, 1998), they do not act alone
ut work with entrepreneurs based on NGOs (Betsill and Corell,
001; Price, 1998) and transnational advocacy networks (Keck and
ikkink, 1998), including epistemic communities with recognised
laims of policy relevant expertise (Haas, 1992). Mytelka and Smith
2002), for instance, show how interactions between policy mak-
rs and academics inside the OECD and European Commission led
o a co-evolution of policy ideas and innovation theory. This pro-
ess reconﬁgured the conceptualisation of innovation and suitable
olicy instruments, inserting RTD and innovation policy as part of
ider policy objectives such as growth. In this case, these organ-
sations functioned as protected spaces in which heterodox ideas
n objectives and instruments of public policy could develop into
ew rules.
These interactions also support the processes of socialisation
hrough which IGOs attempt to diffuse and enforce norms, which
nvolve state and private actors (Clegg, 2010; Zürn and Checkel,
005). IGOs have traditionally diffused norms via state ratiﬁcation
f legally binding treaties whose compliance will often be moni-
ored by their own staff. Increasingly, however, they have expanded
heir governance capacity, and effectiveness, by changing and regu-
ating behaviour of private actors (Abbott and Snidal, 2010). Abbott
nd Snidal call these new practices orchestration. In orchestration,
GOs also rely on the authority afforded by their mandates, moral
tanding and technical expertise to reach out to private actors and
nstitutions, collaborating with them, supporting and shaping their
ctivities. Through orchestration, IGOs decrease political frictions
hat usually hinder public-private and private–private collabora-
ion; reduce transaction costs and bargaining problems through the
dentiﬁcation of participants and enabling negotiations; decrease
istrust by acting as a neutral broker and offset power imbalances
y assisting weaker participants (2010, p.337).
For rationalists and constructivists alike, being perceived as
ndependent actors exercising a neutral, impartial, value-neutral
nowledge to transform interstate relations is central to IGOs’ legit-
macy claims (Abbott and Snidal, 1998; Barnett and Finnemore,
004). IGOs gain legitimacy from inﬂuencing state behaviour
hrough the establishment and diffusion of norms, while states
ain international legitimacy by adhering to them (Claude, 1966;
innemore and Sikkink, 1998). Legitimacy is also related to being
een as serving a useful function valued by international society and
ey constituencies which, in turn, secures autonomy and material
esources to perform the job (Barnett and Coleman, 2005).
.4. IGOs and Grand Challenges
Solving Grand Challenges requires the performance of a series of
ollaborative and specialised tasks that individual states lack exper-
ise, time, political capacity or resources to perform alone. There
re, therefore, clear beneﬁts from delegation to knowledgeable
nd neutral actors able to manage collaboration and coordination
ilemmas, facilitate collective decision making, resolve disputes
nd enforce changes in their particular areas of remit. I suggest here
hat IGOs are able to use their autonomy, authority and legitimacy
o tackle Grand Challenges in two ways (Fig. 1):
The ﬁrst is through the re-deﬁnition of societal problems and of
he solutions to them, a process that involves other IGOs, states and
rivate actors. Their mandates secure high level of state support to
ring different aspects of a problem to the agenda. Their technical
xpertise, neutrality and capacity to produce and borrow issue-
peciﬁc knowledge, from states and non-state actors, facilitate the
ask of identifying needs and deﬁning goals and ways to achieve
hem. These activities give directionality to action by establishing
 common vision based on a shared understanding of what should
e done and by whom. 46 (2017) 171–181
The second way relates to the process of changing practices
in line with the new norms, as enforcement agents. This can be
done through treaties directly shaping state behaviour, or through
orchestration supporting the creation of spaces for collabora-
tion involving private actors. IGOs moral authority and neutrality
enhance their appeal as independent brokers in negotiations com-
prising actors with different interests and levels of power, enabling
new arrangements; their capacity to produce expertise, on the
other hand, support the creation of knowledge necessary for the
success of these solutions.
3. Methodology
Research for this paper was conducted 2012–2015 as part of
the ERC project Professions in International Political Economies
(PIPES). The project examined how professionals cooperate and
compete to solve transnational problems in different policy areas.
Its starting point was the analysis of more than 40 reports and
documents on challenges in public health produced by expert com-
mittees and in-house experts at WHO  and member states from
1994 to 2014. This established the centrality of innovation and
IP issues in health, particularly for access to medicines and medi-
cal technologies. Instruments advocated by participating actors in
three expert committees between 2006 and 2012 were reviewed
and my  choice of the two  mechanisms analysed in this paper, the
MPP and WIPO:Re:Search, was  informed by their different levels
of novelty (i.e. challenge to current practices), as well as types of
states and IGOs facilitating the set up and running of their activ-
ities. A more practical consideration was timing: both initiatives
were launched 2010/11, enhancing my  chances of tracing the pro-
cesses that led to their choice and implementation, including access
to the actors involved.
Fieldwork entailed the analysis of dozens of documents from
UNITAID, WHO  and WIPO. This was complemented by partici-
pant observation of meetings in Geneva and Cape Town in 2012,
2013 and 2014; and, in-depth semi-structured interviews with 34
professionals working for IGOs, NGOs, foundations, industry and
national governments participating in the debate on innovation and
access to medicines (Appendix A). The majority of these profession-
als (80%) occupy senior positions, and 21 were directly involved
in the setting up or management of MPP  and WIPO RE:Search.
Interview questions covered involvement in the debate and details
about the implementation and running of the instruments, but also
explored their perceptions of global challenges in health, other
ways to address the connection between STI and health challenges,
and role of national and international organisations in solving prob-
lems. Given this is a relatively small community and there were
conﬁdentiality concerns, information attributed to interviewees
will be cited as personal communication, followed by organisa-
tional afﬁliation.
4. Results
Having proposed two  ways in which IGOs may  contribute to
tackling Grand Challenges in Section 2, this section moves to the
empirical work focusing on the process of norm development.
4.1. Outside pressure: linking lack of access to intellectual
property
The debate on access to medicines attracted global attention
in late 1990s, when developing countries and civil society groups
started to question the impact of TRIPS on the cost and affordability
of medicines. TRIPS required countries to translate into domestic
law global IP standards and extended patent rights from 15 to 20
A. Nilsson / Research Policy 46 (2017) 171–181 175
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medicines debate: the WHO  as the health authority; the WTO  asFig. 1. The role of IGOs include deﬁning problems and solutio
ears. New conditions to issue compulsory licenses were put in
lace, potentially restricting the freedom of states to pursue pub-
ic health policies. NGOs working on health/consumer rights were
he ﬁrst to react, setting in motion a process that would inter-
ect distinct expert and organisational networks (Nilsson, 2017)
n an attempt to evaluate the consequences of the treaty for public
ealth.
The NGO-led international campaign for access to medicines (’t
oen, 2002; Sell and Prakash, 2004) made the connection between
ack of access and high costs driven by IP rights. In 2000, a group
ed by James Love, from the NGO Consumer Project on Technology,
ecured a deal with CIPLA, an Indian generic pharmaceutical com-
any, for the production of $365 a year (1$ a day) anti-retroviral
rugs that were at the time charged between $10.000 and 15.000 a
ear by brand pharmaceutical companies. At the same time, South
frica, trying to deal with HIV/AIDS related problems by passing
egislation to reduce drug costs, was facing legal action and sanction
hreats from developed countries and their industry (Schneider,
002). Under intense political pressure, the WTO  led negotiations
n the Doha Declaration. The declaration reinstated the priority of
ublic health over private IP rights and clariﬁed the use of TRIPS
exibilities2 by countries.
2 On ﬂexibilities, see http://www.wipo.int/ip-development/en/legislative
ssistance/advice trips.html.well as diffusion of norms through treaties and orchestration.
The establishment of the issue of access to medicines in the
transnational agenda, therefore, was  a reaction to an international
trade regime that established global IP rules and mechanisms for
enforcement. This development led experts and activists to ques-
tion the effects of undifferentiated and widespread IP protection
on public health, with the HIV/AIDS pandemic providing a window
for activists to challenge: industry’s claims of no substantial links
between IP and prices; trade agreements that hinder state action to
meet health and development needs and address emergencies; and
business models based on drugs unaffordable to low and middle-
income countries. By the time the Doha Declaration was signed,
access to drugs and IP3 were linked issues, but there was  no clear
deﬁnition of the problem, which actors should be brought into the
debate and the possible solutions. This would be the task of a joint
IGO effort led by the WHO.
4.2. Giving direction by deﬁning the challenge and its solutions
By 2002, three IGOs were directly involved in the access tothe authority to interpret TRIPS’ legal framework; and WIPO as
the authority on IP. WHO  leadership was not simply a result of its
3 There were reports produced by WHO  on the possible impact of TRIPs on health
and  on the ways states could make use of ﬂexibilities published as early as 1997 but
no  attempt to debate the issue in relation to other variables or propose solutions
that built on but went beyond the TRIPS framework.
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ission to promote health, but a response to reinforced state dele-
ation: between 1996 and 2002, its mandate was strengthened by a
eries of resolutions4 aiming at creating policies to increase access
o medicines. In 2003, member states requested the set up of a
ime-limited working group to consider the relationship between
P, innovation and public health. Established in 2004, the Commis-
ion on Intellectual Property Rights, Innovation and Public Health
CIPIH) conducted the ﬁrst international exercise to identify fac-
ors impacting access to medicines. Its terms of reference included
onsidering “the importance and effectiveness of IP regimes and
ther incentive and funding mechanisms in stimulating research
nd the creation of new medicines and products”; and analysing
proposals for improvement to the current incentives and funding
egimes, including IP rights, designed to stimulate the creation of
ew medicines and products” (p.4)
The process, which involved experts working for UN organisa-
ions, governments, NGOs, universities and foundations, included
onsultations with member states, multi-stakeholder meetings,
nd 22 commissioned studies on the subject. With TRIPS and the
oha Declaration guiding the discussion, the CIPIH brought STI to
he centre of the inquiry, including in-depth analyses of national
ystems of innovation in developing countries and of the multi-
aceted and complex innovation cycle from discovery to delivery
f medicines. Recommendations pointed at possible activities that
ould address the problem at national and transnational levels.
ational instruments ranged from R&D strategies to changes in
atent law frameworks, while transnational tasks were mostly
elated to international coordination, provision of information and
echnical support to member states.
The CIPIH paved the way for the establishment of the Inter-
overnmental Working Group on Public Health, Innovation and
ntellectual Property (IGWG), the ﬁrst forum to involve policy-
akers and experts from every WHO  member state, as well as
N agencies, NGOs, industry and foundations. Between December
006 and May  2008, negotiations were conducted in Geneva and
n all WHO  regions. A signiﬁcant event half-way through the nego-
iation was WIPO’s adoption of the Development Agenda (2007),
 request from developing countries for further integration of the
evelopment dimension into policy making on IP protection. The
genda aims to close the knowledge gap and the digital divide
etween wealthy and poor nations and its 45 recommendations5
equire WIPO’s input on norm setting, coordination, governance
nd assessment activities, as well on more traditional technical
ssistance and capacity building activities..3. A global vision and plan of action
Despite disagreements between developed and developing
ountries in relation to IP issues and the extent to which alterna-
4 An overview and link to all WHA  resolutions can be found at the Department
f  Public Health, Innovation, Intellectual Property Division and Trade of the World
ealth Organisation http://www.who.int/phi/documents/en/index.html.
5 http://www.wipo.int/ip-development/en/agenda/.
able 1
omparison between the MPP  and WIPO Re:Search.
WIPO Re:Search 
Original idea WIPO Global Challenges Division
Problem Market failure (TB, Malaria and NTDs) 
Goal  Foster R&D, technology transfer and capacity building 
Governance Led by Bio Ventures for Global Health (BVGH), a non-proﬁt
biotechnology company
Main  Participants Industry, universities, research centres  46 (2017) 171–181
tives models to foment innovation in health are needed (Velásquez,
2014), member states adopted the Global Strategy and Plan of
Action on Public Health, Innovation and Intellectual Property in
May  2008. The strategy comprises 8 elements and 108 related
actions that speak to STI in health and, to some extent, addresses
the failures of directionality, demand articulation, policy coordi-
nation and reﬂexivity identiﬁed by Weber and Rohracher (2012).
With an explicit aim of promoting new thinking on innovation and
access as intertwined goals, the elements cover different mecha-
nisms to ensure needs and demand are identiﬁed with the help of
relevant stakeholders and tailored to national and local particular-
ities. There is a clear emphasis on connections between national,
regional and international policy arenas, complementary actions
required to achieve changes, and suggested time frames. Also in
place are reﬂexive arrangements such as monitoring and reporting
systems for the strategy as a whole and for the different instru-
ments proposed (e.g the Global Observatory on Health R&D, now
fully operational at WHO). Further support was  to be developed in
form of working groups focusing on the current ﬁnancing and coor-
dination of R&D, in 2010 and 2012. A trilateral cooperation between
the WHO, WIPO and WTO  started in 2009 and a joint report on
access and innovation was  released in 2012.
The IGO-led activities described above, therefore, examined the
shortcomings and strengths of the current socio-technical regime
in health to suggest a direction of change, in which new roles for
public and private actors are necessary. As the work progressed,
the deﬁnition of the challenge moved from a tight focus on IP and
particular diseases affecting developing countries to include wider
aspects of the health innovation system. The Global Strategy has
created a common vision and established complementary mech-
anisms and solutions with potential to, in the medium term (15
to 20 years), transform the pharmaceutical R&D system to better
align the goal of supporting needs-driven innovation in tandem
with widespread access.
A signiﬁcant number of instruments and mechanisms to achieve
this goal depend on international leadership, coordination and
technical support. Following a speciﬁc recommendation of the
Global Strategy to examine upstream and downstream patent
pools, the WHO  and WIPO moved to establish the Medicines Patent
Pool and WIPO Re:Search, targeting innovation and access in rela-
tion to HIV/AIDS, NTDs, TB and Malaria. They will be reviewed next.
5. Orchestrating collaboration for innovation
The Medicines Patent Pool (MPP) and WIPO Re:Search were
established in 2010 and 2011, respectively (Table 1).
The MPP  creates economies of scale and facilitates the pro-
duction of new and affordable HIV/AIDS treatments, including
formulations for children, by pooling together multiple patents
and sub-licensing them to generic companies. Its work reduces
transaction costs, simpliﬁes procurement for governments, UN
agencies and foundations, and creates larger markets for ﬁrms in
the process. WIPO Re:Search is an open innovation consortium
able to coordinate research efforts across geographical areas and
types of organisations in relation to R&D and innovation for NTDs,
Medicines Patent Pool
NGOs Knowledge Ecology International and MSF
Market failure (HIV/AIDS medicines for children); lack of
access/affordability
Enhance access and development of needs/user driven innovation
MPP is registered as a Swiss Charity with a governance board
Industry (generic and research pharma/IP holders), NGOs
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alaria and TB, fostering technology transfer and skills develop-
ent between developing and developed countries. Any innovative
roducts developed through the platform are to be produced with-
ut payment of royalties in low-income countries.
Aiming at accomplishing innovation and wide access simul-
aneously, the two instruments match the concept of facilitative
rchestration: they were created to reach out to private actors, col-
aborate with them and shape their activities. In both cases, the
echanisms are ﬁnancially supported by the IGOs that established
hem but primary governance has become the responsibility of
on-proﬁt actors. WIPO contributes to the activities of the MPP,
nd the WHO  provides support for Re:Search.
.1. Creating new spaces
The MPP  and WIPO Re:Search were launched less than a year
part, but their gestation time differed signiﬁcantly. The NGO
edicines Sans Frontier (MSF) ﬁrst proposed the MPP  to the UNI-
AID board in 2006. Work on feasibility and implementation took
hree years and included a preliminary legal review (Gold et al.,
007), a multidisciplinary expert group on design of the Pool and
 Task Force. Opening space for the establishment of the MPP  was
ore complex for at least two reasons: it requires ﬁrms to share
heir proﬁtable IP assets; and the idea was championed by an
pistemic community pushing for changes in IP rules. In fact, the
oncept of a patent pool for medicines, ﬁrst proposed in 2002 by
he NGO Consumer Project on Technology, had been presented to
he WHO  before without success (personal communication, NGO).
 senior ofﬁcer involved in the process summarised the problem:
The WHO  has a very good understanding of the issue and is aware
hat the current innovation system for health is not working but is
nwilling to be involved in polemical issues such as IP rights. They
o not wish to clash with member states like the US and Japan”
personal communication, WHO).
The approving nod towards innovative IP management mech-
nisms given by the CIPIH, in 2006, and the new tasks delegated
o WHO  in connection with the Global Strategy, opened a new
indow for the consideration of instruments like the MPP. The cru-
ial development, however, was the creation of UNITAID, in 2006.
NITAID is also a response to the access to medicines problem
nd was designed to complement work done by the Global Fund,
NICEF and UNAIDS. Despite being a WHO  agency, UNITAID was
et up by Brazil, Chile, France, Norway and the United Kingdom
o function as a ﬁnancial mechanism inﬂuencing prices of drugs
nd diagnostics. The agency uses buyer-side market leverage to
mpact costs and quality of HIV/AIDS, Malaria and TB health prod-
cts for developing countries. The MPP  ﬁts UNITAID’s mission of
mproving access through innovative market-based instruments,
ncluding pro-public health approaches to IP. Moreover, MPP’s aim
f speeding the delivery of second-line and new products for pro-
urement connects with UNITAID’s tasks of anticipating needs and
arkets. Last, but not least, UNITAID’s smaller board does not fully
eplicate disagreements between developed and developing coun-
ries regarding IP, at the same time that its members are important
layers in the ﬁeld. The idea was met  with cautious curiosity: “I
emember the ﬁrst time MSF  explained the MPP. It was  a strange
dea and we did not know whether it was a good or bad one. The
ecision of the board in 2007 was positive, but we  all felt strongly
hat the ﬁrst step was to investigate how to develop it and make it
ork” (personal communication, UNITAID).
WIPO Re:Search, on the other hand, was a product of brain-
torming processes among new experts employed by WIPO to run
hat would become the Global Challenges Division (personal com-
unication, WIPO), created in 2008 to work on the intersection of IP
nd innovation to tackle Grand Challenges in health, climate change
nd food security. As an interviewee closely involved in the process 46 (2017) 171–181 177
explained, the platform is a direct response to recommendations
19 and 20 of the Development Agenda, which requires WIPO to
facilitate access to knowledge and technology, to foster creativity
and innovation, and promote norm-setting activities related to IP
that support a robust public domain in member states. The more
traditional design of WIPO Re:Search, which ﬁts comfortably with
current practices, and the tight connections between WIPO and the
industry, facilitated the task at hand. For WIPO, creating new norms
is about showing different ways of using IP for innovation: “We  do
not aim to modify the system but to sketch out what is unique about
WIPO and to show how IP can contribute to development and inno-
vation even when there is no market incentives. Companies are our
clients after all” (personal communication, WIPO).
5.2. IGOs as brokers
Part of the process of moving these initiatives from ideas to func-
tioning platforms was the capacity of these IGOs to bring actors
with different interests and expertise to work together. Supported
by their moral standing, IGOs were able to build trust and help cre-
ate the knowledge necessary for the implementation and running
of the instruments.
For the MPP, maintaining the support of the countries and
donors on the UNITAID board and enticing industry to enter
negotiations depended on the creation of a public health entity
oriented towards innovation, not an advocacy group demanding
patents (personal communications, UNITAID and MPP). The time
gap between the decision to investigate the proposal and UNITAID’s
ﬁnal decision to sponsor the Pool reﬂects the need to reduce mis-
trust by enabling negotiations involving several actors: UNITAID,
WHO, countries on the board, the Bill & Melinda Gates Foundation
and civil society communities. This was imperative to deﬁne the
scope and mandate of the Pool and navigate divergent interests
and technical difﬁculties, while protecting the interests of weaker
partners. “All board members within UNITAID had a set of concerns
regarding the MPP  and sometimes the nature of their interests was
not very consistent to one another. The whole process was about
this delicate and negotiated language between UNITAID and the
board, this very interesting situation in which the UNITAID sec-
retary was negotiating on behalf of an organisation that did not
exist yet” (personal communication, UNITAID). This process was
captured in a Memorandum of Understanding agreed between the
MPP  and UNITAID in 2010, which includes both immediate and
aspirational goals, and has been renewed in 2016 for ﬁve more
years.
WIPO Re:Search is different because it focuses on less lucrative
diseases (patents that are not yet proﬁtable) and upstream col-
laborations, which in principle require less involvement of actors
outside R&D departments. The leadership of WIPO, however, is
still important in this case. In 2009, in response to the MPP  pro-
posal, GSK set up the Pool for Open Innovation, an industry-based
attempt to coordinate research on NTDs. Despite making available
more than 100 patents related to these diseases, no partnership
was established and these patents are now part of WIPO Re:Search.
WIPO, as the orchestrator, gives companies a clear signal that IP
core principles will be followed and conﬂicts of interest arbitrated
in the course of collaborations, at the same time that the interests
of weaker players, such as less developed/developing countries, are
taken into consideration and protected in line with the Develop-
ment Agenda. Consultations were intense with industry actors, but
also involved member states, academics, associations and foun-
dations. The guiding principles and standards for licensing, for
instance, were not an adaptation of industry templates but devel-
oped in partnership with the Rockefeller and Bill & Melinda Gates
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oundations, a process that has now moved on to setting priorities
or product development (personal communication, WIPO).
.3. Mobilising expertise
In both cases, being able to produce or access information was
ey to the process of facilitating and guiding the design of the
nstruments and the day-to-day running of their activities.
As mentioned above, the implementation of the MPP was pre-
eded by a preliminary legal review, conducted by academics, and
n advisory group. The advisory group brought experts from the
HO, WIPO and WTO  to consider issues raised by the review and
iscuss the range of options available in relation to the design of
he MPP. It had also, in the opinion of some participants, the role of
nhancing trust and legitimacy.“The technical advisory group has
ade the project seem more balanced. The proposal came from
GOs and some people were suspicious of it solely for that reason.
he multi stakeholder expert group tackled this” (personal com-
unications, NGO and member state representative). As a result
f these technical meetings, the MPP  went from being built on the
mplicit assumption that compulsory licenses would be issued if
atent holders did not volunteer their IP, to a strictly voluntary
icense approach. They have also ruled out the initial idea of having
he organisation hosted inside the WHO  or UNITAID, as UN agen-
ies cannot be involved in commercial negotiations for not being
usceptible to lawsuits or prosecution (personal communication,
TO). The latter also applies for WIPO Re:Search.
Once the MPP  was given the go-ahead and a budget by UNITAID,
nowledge produced by the WHO  and WIPO has become essential
or implementation. WIPO was requested to assist the Pool in the
dentiﬁcation of the legal status of 35 patent families (i.e. where in
he world key patents are valid) and, after this ﬁrst stage, to expand
he list to identify relevant patents for potential new products, a
o-called state of the art search. The work on a patent database con-
aining data landscape from different countries had already started
ith external consultants but, without WIPO as intermediary, it
ould be difﬁcult and time consuming to reach regional and local
fﬁces to retrieve information. WIPO was also particularly active in
he compilation of patent status data for pharmaceutical products
rom over 70 countries, a database now openly available for consul-
ation and regularly updated by the MPP, beneﬁting procurement
gencies over the world, such as UNICEF and the Global Fund, as
ell as universities and ﬁrms.
The licences negotiated with patent holders and sub-licensed to
eneric companies by the MPP, on the other hand, are based on a
riority list drawn by the WHO. The list contains existing medicines
or the treatment of HIV/AIDS such as second line ARVs (Anti-
etrovirus drugs) for adults but also includes missing medicines,
he ones yet to be developed. This wish list is the starting point for
egotiations aiming at the development of innovative drugs, par-
icularly for paediatric use. Every licence is negotiated individually
nd the geographical scope of the sub-licensing to generic com-
anies is agreed case by case. While less developed countries are
lways included, middle-income countries are subjected to more
estrictions and might lead to alternative arrangements, such as
egmentation between private and public markets or differenti-
ted royalties. Invitations to sub-licensees are done through an
pen call published in industry publications and sent to companies
hat belong to the WHO  Pre-Qualiﬁcation6 list, but bidders have to
resent an Expression of Interest showing a business rationale. Dif-
6 The Pre-Qualiﬁcation Programme was originally intended to give UN procure-
ent agencies, such as UNICEF, a choice of products meeting various standards
ertiﬁed by WHO. It has become a central service for other agencies and govern-
ents. 46 (2017) 171–181
ferent from traditional patent pools, the MPP  does not sub-license
to any interested party as this could disrupt the generic ARV market
and hinder access efforts (personal communication, MPP).
In WIPO Re:Search, companies, universities and research facil-
ities holding IP assets on NTDs, Malaria and TB make their IP
available, from compounds, unpublished scientiﬁc data and reg-
ulatory material to patents and patent rights, to be consulted and
used for innovation purposes by researchers based anywhere in the
world. The platform is hosted by WIPO to provide a one-stop shop
for data that is not easily found, encouraging new R&D, particularly
in relation to diseases like Chagas and Dengue. Industry partners
include GSK, Merck & Co., Novartis AG, Pﬁzer and Sanoﬁ. Besides
making this global catalogue available, the platform has a Partner-
ship Hub and offers support for licensing activities. The Partnership
Hub is led by Bio Ventures for Global Health (BVGH). BVGH’s
main responsibility is to identify and connect suitable partners
by reviewing their research and partnering interests. Encouraging
small and mid-sized companies to get involved in the global health
area to focus on product development is one of the main targets
of the hub (personal communication, WIPO). If companies wish to
combine IP to develop products, it draws a science plan and takes
part in the licensing process. Licences are royalty free for products
distribution in the least developed countries.
WIPO experts were involved in the creation of the database,
in the development of guiding principles and standards of licens-
ing with the Rockefeller and Bill & Melinda Gates foundations, and
continue to support the initiative. In-house knowledge of the IP
framework and capacity to provide specialised patent information,
such as legal status and state of the art, is a crucial complement to
BVGH’s job of drawing science plans and coordinating partnerships.
WIPO experts have developed mediation and arbitration proce-
dures in form of a template that can be adapted to different cases
and contribute to the quality and length of the partnerships (per-
sonal communication, WIPO). Technical expertise provided by the
WHO  in relation to public health needs and opportunities is also
available. This includes questions related to patents from neigh-
bouring ﬁelds, for instance animal health, and their relevance for
the neglected tropical diseases WIPO Re:Search is trying to bring
solutions to.
The platform is also being used to diffuse knowledge to member
states, with IP management seminars offered to developing country
members. Distance learning modules based on the Trilateral Report
can be accessed through the WIPO Academy.
5.4. New norms contributing to system transformation?
The MPP  had, by mid-2016, negotiated licenses on 12 prior-
ity ARVs from seven different patent holders, with more than 50
product development projects in the pipeline. It has established
the Paediatric HIV Treatment Initiative with UNITAID and Drugs
for Neglected Diseases Initiative (DNDi) to speed development and
production of missing formulations for children (MPP, 2014) and
generic partners have distributed 3,5 billion doses of low cost prod-
ucts to 121 low and middle-income countries. WIPO Re:Search
had, by May  2016, established 100 collaborations and partnerships,
with activities ranging from sharing of data to hosting scientists
and access to research facilities. Collaborations established so far
involve, for example, an agreement between Merck & Co. and
Emory University regarding a purifying membrane-protein for a
new TB treatment, and a partnership between the National Institute
of Immunology in New Delhi and GSK to study molecular signalling
pathways of malaria parasites.While it might be too early to give a verdict on how success-
ful they are in delivering health innovation, it is fair to say that
the MPP  and WIPO Re:Search introduce new norms that contribute
towards structural changes in pharmaceutical R&D. Despite their
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ifferences – WIPO Re:Search is based on collaborations that ﬁt
urrent industry practices and the MPP  is a more radical experi-
ent, requiring stronger protection and support to function – their
ctivities lay the foundations for a different approach to innovation
n health by (1) adopting a targeted priority setting approach to
lign R&D efforts with public health demands and needs (2) coor-
inating international cooperation involving novel combinations
f public and private actors, including foundations and end-users,
ith particular efforts to integrate partners from developing coun-
ries (3) employing and advising on IP management strategies able
o leverage innovative outcomes while protecting the rights of dif-
erent actors (4) ensuring broad dissemination of knowledge and
nformation, from support on legal and technical issues to contin-
ous provision of data that have been previously unavailable or
ifﬁcult to access.
By producing knowledge and reducing information asym-
etries, transaction costs and mistrust between social groups
nvolved in the socio-technical regime, these instruments disrupt
raditional patterns of power relations and pave the way for a
ifferent approach to innovation that can be replicated beyond
eglected diseases that disproportionally affect developing coun-
ries. Examples of health challenges that can be tackled by similar
rrangements in the near future are the urgent problem of antimi-
robial resistance, as well as R&D efforts against future outbreaks
f infectious diseases (e.g. Ebola or Zika).
. Conclusions
This paper argues that IGOs can contribute to the system trans-
ormations required by Grand Challenges by creating norms that
nﬂuence socio-technical regimes connected to these problems.
he rules and practices they establish have the potential to question
spects of socio-technical regimes linked to Grand Challenges, cre-
ting tensions and misalignments able to trigger the reorientation
hat precede system transformation (Geels and Schot, 2007).
In the case of global health, the authority, autonomy and
egitimacy to develop new rules were supported both by state del-
gation, in form of successive strengthening of WHO  and WIPO
andates, and IGOs’ capacity to create knowledge while engag-
ng with state and non-state actors. This process, however, did not
mply consensus or overlapping interests. There were considerable
isagreements regarding problem and solutions, with aspects of the
lobal Strategy watered down by powerful states. Extended dele-
ation, however, supported IGOs’ agency as being in line with the
ollective will of member states. This has allowed them to create
paces for ideas that differ or even go against established interests
nd practices in order to provide solutions to the challenge at hand.
ustifying these ideas, in turn, was connected with their capacity to
roduce knowledge, a process supported by of an extensive multi-
takeholder examination of the current health innovation system.
The establishment of a new direction in form of a Global Strategy
as followed by orchestration activities for the implementation
f the MPP  and WIPO Re:Search. This process also depended on
GO’s authority stemming from delegation (i.e. the Strategy itself),
oral standing and expertise. Operating as impartial and knowl-
dgeable brokers, WHO/UNITAID and WIPO engaged actors with
ifferent interests and capacity in various forms of collaboration.
his was particularly important in the case of the MPP, which relies
n practices that differ substantially from incumbents’ preferences,
ut also played a role in WIPO Re:Search. Part of establishing
rust involved creating knowledge: guiding principles and stan-
ards developed by WIPO established clear rules and arbitrating
rocedures; the list of existent and yet to be developed medicines
reated by the WHO  for the MPP  gave a medical/needs driven ratio-
ale for the negotiations of speciﬁc patents and delineated the 46 (2017) 171–181 179
necessary types of collaboration. Provision of technical expertise
on medical/pharmaceutical and patent issues was also central for
implementation and continues to support their main tasks.
The collaboration between IGOs for the development and dif-
fusion of norms that cut across international regimes, reviewed
in this paper, highlights a yet overlooked area in the literature
on IGOs and international regimes. These increasingly common
interactions, partly connected with the distinctive complexity of
Grand Challenges, raise questions about the current understanding
of international norm development as reﬂecting the organisational
culture and expertise of particular bureaucracies, as well as the
extent to which articulating and diffusing norms become a collec-
tive exercise that disrupts attempts from individual IGOs to control
issues and claim authority over them. This opens up new avenues
for the exploration of how the interplay between multiple bureau-
cratic cultures and member state interests may  shape the way
policy preferences and IGOs themselves change, potentially speak-
ing to a growing scholarship focusing on norms as contingent and
contested (Seabrooke, 2010; p.265).
The paper also contributes to the Grand Challenges literature
by further developing our understanding of the different actors
and activities that play a role in open-ended processes of sys-
temic transformations. By focusing on IGOs, this paper shows how
interventions outside the nexus government-driven R&D and fund-
ing address these shared problems while actively contributing to
change by establishing directionality. Examining agency outside
the traditional STI spectrum showcases the potential of differ-
ent actors to inﬂuence socio-technical regimes of innovation and
highlights another way  in which horizontal policy coordination
between STI and thematic areas can occur at transnational level.
The departure point here is not innovation policy arenas that reach
out to other areas, but the opposite: organisations with authority
in policy areas related to Grand Challenges bring STI concerns into
their sectoral debate, making the connection between them and
proposing action.
The processes analysed here also speak to the transition schol-
arship by suggesting that IGOs have functions that mimic transition
policies, centred around a speciﬁc problem area and underpinned
by the development of joint societal visions and orchestration of
activities that reinforce a desired direction. The empirical material
shows how norms developed by IGOs can insert tensions in socio-
technical regimes as a response to external pressure, and hints at
ways in which both incremental/adaptive and unorthodox activ-
ities may  happen simultaneously in response to the new norm.
While WIPO Re:Search addresses the re-deﬁnition of innovation
and access as two sides of the same coin through a platform that
keep the centrality of strong IP protection for innovation in health,
as in the model preferred by incumbents, the MPP  moves towards
novel arrangements to achieve needs-driven and affordable prod-
ucts.
Constrained to the case of global health, this analysis is limited.
In addition, the policy area might have facilitated IGOs’ agency.
Firstly, the nature of the issue enhances the likelihood of out-
side pressure from social movements. Research suggests that some
problems are more likely to be taken up by social movements at
transnational level, with those involving bodily harm to vulnera-
ble individuals being speciﬁcally relevant, especially when a short
and clear causal chain and culprits can be established (Keck and
Sikkink, 1999). The linking of the suffering caused by the HIV/AIDS
pandemic to unaffordable prices of medicines and IP by NGOs is a
key factor behind states’ decision to negotiate the Doha Declaration
and delegate more power to IGOs to investigate the problem. This
type of political pressure is weaker in less sensitive areas, such as
transport and energy. Secondly, the declining efﬁciency of the phar-
maceutical industry in developing new drugs despite the strong
reliance on IP rights, coupled with the rise of incremental innova-
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ion in form of ‘me  too’ drugs, could mean internal tensions were
lready propelling change and weakening incumbent resistance to
t.
Despite these limitations, the case made here for IGOs as author-
tative actors able to perform tasks that are part and parcel of
pen-ended processes that lead to transformations required by
rand Challenges still stands. This is particularly relevant when
here are growing calls for the creation of new organisations to
erform similar roles.
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ppendix A. List of interviewees.
Organisational
afﬁliation
Direct involvement
in instruments
Date/place of
interview
MPP  Yes February 2012, Geneva
MPP  Yes March 2012, phone
MPP  Yes February 2014, phone
MPP  Yes May  2013, Geneva
MPP  Yes March 2013, Geneva
WHO  Yes May  2013, Geneva
WHO  Yes December 2013, phone
WHO  Yes June 2013, phone
WHO  Yes May  2013, Geneva
WIPO Yes March 2012, Geneva
WIPO Yes March 2012, Geneva
WIPO Yes March 2012, Geneva
WIPO Yes October 2013, Geneva
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